Disease · MONDO_0019019

osteogenesis imperfecta

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. osteogenesis imperfecta. Diseases, record MONDO_0019019. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019019

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: osteogenesis imperfecta; Open Targets
Open Targets ID: MONDO_0019019; Open Targets
Other names: Lobstein disease, OI, Osteopsathyrosis, Porak and Durante disease, brittle bone disease, glass bone disease; Open Targets
Disease Ontology: DOID:12347; Disease Ontology
MeSH: D010013; MeSH
NCI Thesaurus: C26837; NCI Thesaurus
Orphanet: ORPHA:666; Orphanet
Highest stage of its drugs: Approval, for 1 of its 17 drugs, from TTD; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TERIPARATIDE	CHEMBL525610	Protein	Approval	TTD	3	2	2	Drugs and targets
SETRUSUMAB	CHEMBL4297918	Antibody	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
DENOSUMAB	CHEMBL1237023	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PAMIDRONIC ACID	CHEMBL834	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
SOMATROPIN	CHEMBL1201621	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
RISEDRONIC ACID	CHEMBL923	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ROMOSOZUMAB	CHEMBL2107874	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CALCIUM	CHEMBL1200496	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FDPS	Farnesyl pyrophosphate synthase	3	Farnesyl diphosphate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/2224	Drugs and targets
SOST	Sclerostin	2	Sclerostin inhibitor	Phase 3	https://conductscience.org/library/genes/50964	Drugs and targets
GHR	Growth hormone receptor	1	Growth hormone receptor agonist	Phase 3	https://conductscience.org/library/genes/2690	Drugs and targets
PLG	Plasminogen	1	Plasminogen inhibitor	Unknown	https://conductscience.org/library/genes/5340	Drugs and targets
PPIA	Peptidyl-prolyl cis-trans isomerase A	1	Cyclophilin A modulator	Phase 1	https://conductscience.org/library/genes/5478	Drugs and targets
PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	1	Parathyroid hormone receptor agonist	Approval	https://conductscience.org/library/genes/5745	Drugs and targets
TGFB1	Transforming growth factor beta-1 proprotein	1	Transforming growth factor beta-1 inhibitor	Phase 1	https://conductscience.org/library/genes/7040	Drugs and targets
TGFB2	Transforming growth factor beta-2 proprotein	1	Transforming growth factor beta-2 inhibitor	Phase 1	https://conductscience.org/library/genes/7042	Drugs and targets
TGFB3	Transforming growth factor beta-3 proprotein	1	Transforming growth factor beta-3 inhibitor	Phase 1	https://conductscience.org/library/genes/7043	Drugs and targets
TNFSF11	Tumor necrosis factor ligand superfamily member 11	1	Tumor necrosis factor ligand superfamily member 11 inhibitor	Phase 3	https://conductscience.org/library/genes/8600	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02352753	Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI	Phase 3	153	2022-12-28	Osteogenesis Imperfecta	DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT00106028	Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children	Phase 3	143	2010-06-28	Osteogenesis Imperfecta	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03118570	A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804	Phase 2	112	2022-03-02	Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV	SETRUSUMAB	Its record names the disease	ClinicalTrials.gov
NCT00131469	Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta	Phase 4	79	2019-04-24	Osteogenesis Imperfecta	TERIPARATIDE	Its record names the disease	ClinicalTrials.gov
NCT03638128	Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta	Phase 3	75	2022-12-20	Osteogenesis Imperfecta (OI)	DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT00001305	Growth Hormone Therapy in Osteogenesis Imperfecta	Phase 3	42	2019-01-29	Osteogenesis Imperfecta	SOMATROPIN	Its record names the disease	ClinicalTrials.gov
NCT00005901	Pamidronate to Treat Osteogenesis Imperfecta in Children	Phase 3	34	2016-03-01	Osteogenesis Imperfecta	PAMIDRONIC ACID, SOMATROPIN	Its record names the disease	ClinicalTrials.gov
NCT04545554	Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta	Phase 1	25	2024-04-15	Osteogenesis Imperfecta	ROMOSOZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03064074	Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta	Phase 1	11	2024-10-08	Osteogenesis Imperfecta	FRESOLIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT05312697	Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta	Phase 2	2	2025-07-23	Osteogenesis Imperfecta	SETRUSUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Denosumab 6-Month Dosing Regimen vs Denosumab 3-Month Dosing Regimen: deaths from any cause	0 of 153	0 of 60	213	NCT02352753	Trial comparisons
Denosumab 6-Month Dosing Regimen vs Denosumab 3-Month Dosing Regimen: serious adverse events	52 of 153	12 of 60	213	NCT02352753	Trial comparisons
Teriparatide (FORTEO) vs Placebo: deaths from any cause	0 of 38	1 of 40	78	NCT00131469	Trial comparisons
Teriparatide (FORTEO) vs Placebo: serious adverse events	0 of 38	0 of 40	78	NCT00131469	Trial comparisons
Active Comparator: 1 vs Active Comparator: 2: serious adverse events	0 of 19	0 of 15	34	NCT00005901	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27669735	RESULT	1	PubMed
22407910	RESULT	1	PubMed
18843680	RESULT	1	PubMed
18404382	RESULT	1	PubMed
42470570	DERIVED	4	PubMed
39012717	DERIVED	1	PubMed
38261781	DERIVED	1	PubMed
35113812	DERIVED	1	PubMed
24463451	DERIVED	1	PubMed
23927913	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019019

GET https://conductscience.org/api/diseases/v1/MONDO_0019019/trials?page=2

API reference For AI assistants